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The FcRH4 transmembrane molecule, a member of the Fc receptor homologue family, can 
potently inhibit B cell receptor (BCR) signaling. We show that cell surface expression of this 
immunoregulatory molecule is restricted to a subpopulation of memory B cells, most of 
which lack the classical CD27 marker for memory B cells in humans. The FcRH4
 
 
 
 and 
FcRH4
 
 
 
 memory B cells have undergone comparable levels of immunoglobulin isotype 
switching and somatic hypermutation, while neither subpopulation expresses the transcription 
factors involved in plasma cell differentiation. The FcRH4
 
 
 
 memory cells are morphologically 
distinctive large lymphocytes that express the CD69, CD80, and CD86 cell activation 
markers. They are also shown to be poised to secrete high levels of immunoglobulins in 
response to stimulation with T cell cytokines, but they fail to proliferate in response either 
to BCR ligation or 
 
Staphylococcus aureus
 
 stimulation. A heightened expression of the CCR1 
and CCR5 chemokine receptors may facilitate their preferential localization in lymphoid 
tissues near epithelial surfaces. Cell surface FcRH4 expression thus marks a unique population 
of memory B cells with distinctive morphology, functional capabilities, and tissue localization.
 
B lineage cells are generated in the bone marrow
throughout life in humans (1, 2). After the func-
tional rearrangement of heavy and light chain
immunoglobulin genes during the progenitor
(pro-B) and precursor (pre-B) cell stages in dif-
ferentiation, naive B cells selected for nonself
reactivity migrate from bone marrow to colonize
the peripheral lymphoid tissues, including the
spleen, lymph nodes, tonsils, intestinal Peyer’s
patches, and appendix (for reviews see references
3, 4). Within the secondary lymphoid tissues,
naive B cells bearing cell surface IgM and IgD
receptors are activated through antigen stimula-
tion and T cell help to form germinal centers,
wherein they undergo proliferation, immuno-
globulin class switching, and variable region
somatic hypermutation to produce higher affinity
antibodies (5). On their departure from germinal
centers, B cells may undergo differentiation into
immunoglobulin-secreting plasma cells or be-
come memory B cells. Germinal center B cells
in humans express the TNF receptor family
member CD27. The expression of CD27 may
also persist after cells leave the germinal center to
serve as a practical marker for memory B cells (6,
7). Upon interaction of CD27 with its CD70
ligand, recruitment of TRAF2 and TRAF5 to
the CD27 intracellular domain leads to the
activation of JNK and NF-
 
 
 
B
 
 
 
(8, 9). The sig-
nals transduced by CD27 on memory B cells
enhance plasma cell differentiation (10, 11).
The generation of memory B cells is an
important component of the adaptive immune
response. Antibodies made by antigen-reacti-
vated memory B cells are predominantly of a
class-switched isotype, and their somatically
mutated variable regions reflect their selection
for higher antigen affinity (12, 13). Following
antigen stimulation, memory B cells may enter
the cell cycle 20–30 h sooner than naive B
cells (14), and their subsequent differentiation
into antibody-secreting plasma cells leads to
higher levels of specific antibodies after sec-
ondary antigenic challenge.
Human B cells have been shown to differ-
entially express five members of a recently
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identified family of immunoglobulin domain–containing
transmembrane molecules (15–17). All of these Fc receptor
relatives possess activating and/or inhibitory motifs in their
cytoplasmic domains and thus have immunomodulatory po-
tential. Although they are variously referred to as Fc receptor
homologues (FcRHs) (15); immunoglobulin superfamily,
FcR, gp42 (17); and immunoglobulin superfamily receptor
translocation-associated (IRTA) (16), for simplicity we use
the provisional FcRH nomenclature here. Previous studies
suggest that FcRH4 is preferentially expressed by memory B
cells (16, 18, 19). Functional analysis of its immunoreceptor
tyrosine-based inhibitory motif–containing intracellular do-
main indicates that, when tyrosine phosphorylated, FcRH4
has potent inhibitory potential for B cell receptor (BCR)-
mediated signaling through the recruitment of protein ty-
rosine phosphatases SHP-1 and/or SHP-2 (18). The present
study defines the cells that bear FcRH4 as a novel subpopu-
lation of memory B cells with distinctive morphology, func-
tion, and tissue localization, characteristics that distinguish
them from the previously identified CD27
 
 
 
 memory B cells.
 
RESULTS
Production of anti-FcRH4 monoclonal antibodies
 
Hybridoma clones producing monoclonal anti-FcRH4 anti-
bodies were generated by immunizing mice with recombi-
nant protein corresponding to the extracellular domain of
FcRH4 and fusion of lymph node B cells with a non–immu-
noglobulin-producing myeloma cell line. The 2A6 hybrid-
oma clone was selected on the basis of ELISA and Western
blot assays demonstrating FcRH4 specificity for its antibody
product. To verify the anti-FcRH4 reactivity of the 2A6
monoclonal antibody with cell surface FcRH4 molecules,
A20-IIA1.6 cells were transiently transfected with a con-
struct in which GFP was fused c-terminally to FcRH4 and
stained with biotinylated F(ab
 
 
 
)
 
2
 
 fragments of this anti-
FcRH4 antibody plus streptavidin coupled to phycoerythrin.
FcRH4 specificity of the 2A6 antibody was indicated by se-
lective staining of FcRH4-transfected cells (Fig. 1 A) and by
immunoprecipitation analysis of recombinant FcRH pro-
teins (Fig. 1 B). Cell surface immunofluorescence analysis of
B cell lines also indicated that the 2A6 antibody does not re-
act with B cell lines that express FcRH1, -2, -3, and/or -5
(Table I) (20, 21).
 
FcRH4 expression is restricted to a subpopulation 
of memory B cells
 
Evidence indicating that memory B cells may preferentially
express FcRH4 messenger RNA (mRNA) was presented in
an earlier study (18). When immunofluorescence analysis
was performed, a discrete subpopulation of the CD19
 
 
 
 ton-
sillar B cells (9.49 
 
 
 
 4.95% SEM, 
 
n
 
 
 
 
 
 24) was found to ex-
press cell surface FcRH4 (Fig. 2 A). When the IgD and
CD38 markers were used to divide tonsillar B cells into na-
ive (IgD
 
 
 
/CD38
 
 
 
), pregerminal center (IgD
 
 
 
/CD38
 
 
 
),
germinal center (IgD
 
 
 
/CD38
 
 
 
), plasma cell (IgD
 
 
 
/CD38
 
 
 
),
and memory B cell subpopulations (IgD
 
 
 
/CD38
 
 
 
)
 
Table I.
 
Immunofluorescence analysis of FcRH4 expression by 
CD19
 
 
 
 B cells in different tissues and B lineage cell lines
 
Tissue/cell lines Tumor cell types
FcRH4
 
 
 
 B cells
(no. of samples)
 
 %
 
Bone marrow 
 
 
 
0.5 (
 
n
 
 
 
 
 
 2)
Peripheral blood
 
 
 
0.2 (
 
n
 
 
 
 
 
 8)
Tonsils  9.5 
 
 
 
 4.95 SEM 
(
 
n
 
 
 
 
 
 24)
Spleen
 
 
 
0.5 (
 
n
 
 
 
 
 
 4)
Nalm16 Acute lymphoblastic leukemia 
(pro–B cell line)
 
 
 
0.1
697 Acute lymphoblastic leukemia 
(pre–B cell line)
 
 
 
0.1
EU12 Acute lymphoblastic leukemia 
(pro–B/pre–B cell line)
 
 
 
0.1
Daudi Burkitt’s lymphoma (EBV
 
 
 
)
 
 
 
0.1
Raji Burkitt’s lymphoma (EBV
 
 
 
)
 
 
 
0.1
Namalwa Burkitt’s lymphoma (EBV
 
 
 
)
 
 
 
0.1
BJAB Burkitt’s lymphoma (EBV
 
 
 
)
 
 
 
0.1
Ramos Burkitt’s lymphoma (EBV
 
 
 
)
 
 
 
0.1
WSU-1 Diffuse large B cell lymphoma
 
 
 
0.1
SUDHL-6 Diffuse large B cell lymphoma
 
 
 
0.1
NCI-H929  Multiple myeloma  84
RPMI-8226 Multiple myeloma  24
U226 Multiple myeloma  10
Figure 1. Specificity analysis of the 2A6 anti-FcRH4 monoclonal 
antibody. (A) A20-IIA1.6 B cells lacking the Fc RIIB receptor were transiently 
transfected with expression constructs encoding a FcRH4-GFP fusion protein 
(filled histogram) or GFP-only control constructs (open histogram). Cells 
were stained with biotinylated F(ab )2-fragments of anti-FcRH4 antibodies 
and streptavidin-PE. Analysis gates were set on the GFP  cell fraction of 
transfected cells. (B) Lysates from 293T cells transiently transfected with 
the FcRH-GFP fusion constructs, HA-FcRH fusion constructs or empty 
vector control constructs were subjected to immunopreciptation with the 
2A6 anti-FcRH4 antibody. The immunoprecipitates (top) and whole cell lysates 
(bottom) were separated via SDS-PAGE and probed by Western blotting 
with anti-GFP antibodies and anti-HA antibodies, respectively. The appearance 
of a faint band of immunopreciptated HA-FcRH5 on prolonged exposure of 
the blot (not shown), suggested weak FcRH5 cross-reactivity but the 2A6 
antibody was found to be nonreactive with native FcRH5 bearing cell lines, 
SUDHL-6 and Namalwa (Table I) (reference 21). 
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(22, 23) (Fig. 2 B), the FcRH4-bearing cells were found
primarily in the IgD
 
 
 
/CD38
 
 
 
 memory B cell fraction (Fig.
2 C), although a small subset of tonsillar FcRH4
 
 
 
 cells ex-
pressed low levels of IgD (1.13 
 
 
 
 1.26% SEM, 
 
n
 
 
 
 
 
 20).
One third of the IgD
 
 
 
/CD38
 
 
 
 memory B cells were
FcRH4
 
 
 
 (35 
 
 
 
 10.65% SEM, 
 
n
 
 
 
 
 
 11), and most of these
did not express CD27 (72.1 
 
 
 
 8.3% SEM, 
 
n
 
 
 
 
 
 10). Like-
wise, analysis of the FcRH4
 
 
 
/IgD
 
lo
 
 subset indicated that
most were CD27-negative (77.1 
 
 
 
 11.9% SEM, 
 
n
 
 
 
 
 
 10)
(Fig. 2 E). Conversely, memory B cells lacking FcRH4 ex-
pression were overwhelmingly CD27-positive. Light scatter
analysis of the IgD
 
 
 
/CD38
 
 
 
 memory B cell compartment
suggested that the FcRH4
 
 
 
 cells are larger than the FcRH4
 
 
 
cells (Fig. 2 D), and this was true for FcRH4
 
 
 
 IgD
 
lo
 
 cells as
well (not depicted). Microscopic examination of the isolated
subpopulations of memory B cells confirmed the relatively
large size of the FcRH4
 
 
 
 cells and indicated that they have
distinctive morphological features, which include the posses-
sion of prominent nucleoli and an extensive cytoplasm that is
rich in mitochondria. Rough endoplasmic reticulum was not
abundant in either lymphocyte type (Fig. 2 F).
 
FcRH4-bearing cells have hypermutated immunoglobulin 
variable regions
 
Defining features of memory B cells include the expression
of switched immunoglobulin isotypes and variable region
somatic mutations. Analysis of the immunoglobulin isotypes
expressed by FcRH4
 
 
 
 memory B cells indicated that the
majority of these cells express IgG (63.17 
 
 
 
 14.92% SEM,
 
n
 
 
 
 
 
 4), followed by cells expressing IgA (27.68 
 
 
 
 2.46%
SEM, 
 
n
 
 
 
 
 
 4) or IgM (11.05 
 
 
 
 5.56% SEM, 
 
n
 
 
 
 
 
 4). To eval-
uate the mutational status of the immunoglobulin V
 
H
 
 genes
in FcRH4
 
 
 
 and FcRH4
 
 
 
 memory B cells, we amplified
V
 
H
 
3 gene family regions via RT-PCR of FACS-purified
cells. Sequence analysis of these V
 
H
 
 region transcripts indi-
cated that the FcRH4
 
 
 
 and FcRH4
 
 
 
 subpopulations of ton-
sillar IgD /CD38  B cells have comparable somatic muta-
tion frequencies (mean 4.35   2.43% SEM, n   26 vs. 4.5  
3.29% SEM, n   25). Of the VH3 genes analyzed, only
one sequence in the FcRH4  population was found to be
devoid of mutation. In both subpopulations, the R/S values
were greater for the CDR than for the framework (FR) re-
gion (R/SCDR   2.41 and R/SFR   1.48 for FcRH4  cells
versus R/SCDR    2.47 and R/SFR    1.59 for FcRH4 
cells), suggesting that both types of memory B cells undergo
the affinity selection process in germinal centers. The com-
bined results of this analysis indicate that both FcRH4  and
FcRH4  cells in the IgD /CD38  tonsillar compartment
are bona fide memory B cells.
FcRH4-bearing cells have a distinctive activated phenotype
Because the FcRH4  cells were found primarily in the IgD /
CD38  memory B cell compartment, we examined their ex-
pression of cell surface markers commonly associated with
memory B cells. Expression levels for the IL-2 receptor   chain
(CD25) were found to be low to undetectable. Like their
FcRH4  counterparts, the FcRH4  cells were positive for
CD20, CD21, CD23, CD32, CD40, CD44, CD69, CD80,
CD84, and CD86 but were negative for the CD138 plasma cell
marker. Most of these cell surface markers were expressed at
slightly higher levels on FcRH4  cells, but this may not equate
with higher receptor density given their relatively large size.
The much higher level of CD20 on the larger FcRH4  cells
nevertheless represents a notable difference. Conversely, the
FcRH4  cells express lower levels of the complement receptor
2 (CD21) than their FcRH4  counterparts (Fig. 3).
Figure 2. Analysis of FcRH4 expression on B cell subpopulations in 
human tonsils. (A) CD19-purified tonsillar B cells were stained with anti-
CD38, anti-IgD, and anti-FcRH4. A subpopulation of  10% were stained 
positively for cell surface FcRH4 (M2 gate). M1 gate is the entire population 
of CD19 positive tonsillar B cells. (B) Analysis of the entire population of 
tonsillar B cells (M1 gate) and (C) FcRH4  tonsillar B cells (M2 gate) for 
expression of CD38 and IgD. (D and E) CD19-purified tonsillar B cells were 
stained for CD38, IgD, CD27, and FcRH4. The gate was set on the CD38 /IgD  
memory B cell population and analyzed for forward scatter (FSC) versus 
FcRH4 and CD27 versus FcRH4 expression, respectively. Note the increased 
forward light scattering of the FcRH4  subpopulation (D) and the discordant 
FcRH4 and CD27 expression (E). (F) Wright-GIEMSA staining and electron 
microscopy of FcRH4  (top) and FcRH4  (bottom) memory B cells reveals 
their striking morphological differences. Bar, 2  m.MEMORY B CELL SUBSETS IN HUMANS | Ehrhardt et al. 786
Although often used as a plasma cell marker, CD138 is
not found on all plasma cells (24). To verify that the
FcRH4  memory B cells have not yet begun to undergo
plasma cell differentiation, we analyzed mRNA levels of
transcription factors that promote plasma cell differentiation,
namely BLIMP-1 (25), the spliced isoform of XBP-1 (26)
and IRF4 (27), in the FcRH4  and FcRH4  memory cells,
germinal center cells, and plasma cells. BCL-6 levels were
also assessed. Transcripts of BLIMP-1, XBP-1, and IRF4
were barely detectable in either FcRH4  or FcRH4  mem-
ory B cells or in the germinal center B cells, whereas a
prominent signal was observed for these transcripts in plasma
cells (Fig. 4 A). BCL-6 mRNA was detected in germinal
center cells and at lower levels in FcRH4  memory cells.
These findings indicate that the FcRH4  memory B cells
have a distinctive nonplasma cell phenotype.
Tissue distribution and chemokine receptor profile of 
FcRH4  versus FcRH4  memory B cells
FcRH4 mRNA analysis (18) and the aforementioned dem-
onstration that FcRH4 is expressed on a subpopulation of
the memory B cells suggest stringent regulatory control of
FcRH4 expression. Although cell surface FcRH4 is detect-
able on  10% of the tonsillar B cells, FcRH4  B cells were
rarely detected in bone marrow, spleen, and blood samples
from healthy individuals. In contrast, CD27  B cells were
relatively abundant among B cell populations in the tonsils
(53.0   12.7% SEM, n   11), blood (30.8   16.2% SEM,
n   12), and spleen as expected (6, 7, 22). This highly selec-
tive pattern of FcRH4 expression was also reflected by the
fact that almost all of the B lineage cell lines that were ana-
lyzed were negative for FcRH4 expression. The notable ex-
ceptions were multiple myeloma cell lines, three of which
were found to express variable levels of FcRH4 mRNA
and protein (Table I and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20050879/DC1).
Figure 3. Profile analysis of cell surface markers expressed by 
FcRH4  and FcRH4  memory B cells. Purified tonsillar CD19  B cells 
were stained for CD38, IgD, FcRH4, and the indicated cell surface anti-
gens. The analysis gate was then set on the IgD /CD38  memory B cell 
population. Staining of FcRH4  cells is indicated by a solid line; staining 
of FcRH4  cells is indicated by a dashed line. The filled gray histogram 
indicates background staining with an irrelevant isotype-matched 
control antibody.
Figure 4. Quantitative assessment of transcription factor and 
chemokine receptor mRNA expression by FcRH4  and FcRH4  
memory B cells. (A) mRNA derived from FcRH4  and FcRH4  memory 
B cells, germinal center (GC) B cells and plasma cells (PC) and (B) from 
FcRH4  and FcRH4  memory B cells was used as template for real-time 
PCR analysis of the indicated genes. All values are normalized to expression 
levels of the large subunit of the RNA-polymerase 2. Values represent 
the mean   SEM from three independent cDNA preparations from three 
different tonsil samples, with each PCR performed in duplicate.JEM VOL. 202, September 19, 2005 787
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CCR7 expression has been used to distinguish memory T
cells (CCR7 ) from effector T cells (CCR7 ) (28), and the
chemokine receptors expressed by these T cell subpopulations
may influence their tissue localization pereferences. We there-
fore surveyed the chemokine receptor expression profiles for
the FcRH4  and FcRH4  subpopulations of memory B cells.
While differences were not seen for most chemokine receptors,
including CCR7 and CXCR4, mRNA levels for CCR1 and
CCR5 were strongly up-regulated in FcRH4  cells in com-
parison with the FcRH4  memory B cells (Fig. 4 B). These
findings suggest that localized production of the chemokine
ligands for these two chemokine receptors may influence the
tissue localization pattern of FcRH4  memory B cells.
FcRH4  and FcRH4  memory B cell responses to different 
activating stimuli
Whereas BCR ligation induces the activation and prolifera-
tion of memory B cells (29), the intracellular domain of
FcRH4 has been shown to have a profound inhibitory effect
on BCR-mediated signaling (18). To evaluate the responsive-
ness of FcRH4  versus FcRH4  cells to BCR-mediated
stimulation, the purified subpopulations of memory B cells
were stimulated with either intact anti-immunoglobulin anti-
bodies or their F(ab )2 fragments. The two subpopulations
were also analyzed for responsiveness to the polyclonal activa-
tor Staphylococcus aureus Cowan strain (SAC) and the cytokines
IL-2, IL-10, and CD40L. The assessment of thymidine incor-
poration after 40 h in culture indicated that FcRH4  cells re-
spond well both to BCR ligation and cytokine stimulation
(Fig. 5 A). In contrast, FcRH4  cells responded to cytokine
stimulation but not BCR ligation. Moreover, SAC treatment
barely elicited a detectable response of the FcRH4  cells (Fig.
5 A), and treatment with SAC did not affect the activation re-
sponse to IL-2, IL-10, or CD40L (unpublished data).
Because memory B cells have been shown to differentiate
into immunoglobulin-secreting cells in response to in vitro
treatment with the T cell derived cytokines IL-2, IL-4, and IL-
10, or following CD40 ligation by CD40L (10, 30), we mea-
sured the levels of immunoglobulin secretion by purified
FcRH4  and FcRH4  memory B cells after stimulation with
cytokines and CD40L. Analysis of culture supernatants after 4 d
of stimulation indicated that the FcRH4  cells secreted more
immunoglobulin than FcRH4  cells in response to IL-2 and
IL-10 or to IL-2, IL-10, and CD40L (Fig. 5 B). ELISPOT as-
says further indicated that the increased levels of immunoglobu-
lin secretion resulted from increased numbers of immunoglobu-
lin-secreting cells (Fig. 5 C). In keeping with their memory
status, the majority of both FcHR4  and FcRH4  subpopula-
tions of B cells secreted IgG antibodies ( 60%), followed by
subpopulations of lesser abundance that produced IgM or IgA.
We also examined the possibility that the FcRH4 
memory B cells could be induced to express FcRH4 as an
intermediate step in memory B cell differentiation. In these
experiments, the FcRH4  cells were labeled with a succin-
imidyl ester of carboxyfluorescein diacetate (CFSE), a fluo-
rescent dye that is equally distributed between daughter cells.
As anticipated, the stimulation of FcRH4  memory B cells
with IL-2, IL-10, and CD40L led to their proliferation, but
this response was not accompanied by the expression of
FcRH4 within the 48-h interval of observation.
DISCUSSION
The present experiments define two distinctive subpopula-
tions of memory B cells in humans that are distinguishable
Figure 5. Response of memory B cell subpopulations to cytokine 
stimulation and BCR ligation. Analysis of the proliferative response 
and of immunoglobulins secreted by purified FcRH4  (filled bars) and 
FcRH4  (open bars) memory B cells. (A) Cells were cultured for 40 h with 
or without the indicated stimuli. After addition of 3H-thymidine for an 
additional 10 h, the cells were harvested and 3H-thymidine incorpora-
tion assessed. (B) Cells were cultured for 96 h before the supernatant of 
the cells was analyzed for secreted immunoglobulins via capture ELISA. 
Data shown are the mean   SD one representative of four or more 
experiments performed with different tonsil samples. (C) Analysis of IgA, 
IgG, and IgM secretion by FcRH4  and FcRH4  memory B cells after 
stimulation. Cells isolated and stimulated as in panel B were plated onto 
ELISPOT plates coated with isotype-specific antibodies and after incuba-
tion for 5 h the number of antibody-secreting cells was assessed. Shown 
is a representative experiment out of at least three independently 
performed experiments.MEMORY B CELL SUBSETS IN HUMANS | Ehrhardt et al. 788
on the basis of whether or not they express the transmem-
brane immunoregulatory FcRH4 molecule. The FcRH4-
bearing cells that we characterized are confined largely
within the IgD /CD38  memory B cell population in the
tonsils, although a minor subset of the FcRH4  cells ex-
pressed low levels of IgD. Although FcRH4-bearing B cells
comprise  10% of the tonsillar B cells, they are rarely de-
tectable in the circulation and were also rarely seen in the
bone marrow or spleen. This unusual distribution pattern has
been noted in another study that employed a different
monoclonal anti-FcRH4 antibody to assess the tissue distri-
bution of FcRH4-bearing cells (Polson, A., personal com-
munication). FcRH4  cells have been detected by immuno-
histochemical analysis in tonsils, Peyer’s patches, lymph
nodes, and in inflamed tissues from patients with Hashi-
moto’s thyroiditis, Sjorgen’s syalodenitis, and Helicobacter
pylori–associated gastritis (19). We conclude from these ob-
servations that the FcRH4-bearing B cells represent a spe-
cialized tissue-based subpopulation of memory B cells.
The unusual nature of the FcRH4-bearing subpopula-
tion of memory B cells is emphasized by the lack of FcRH4
expression by any of 10 leukemia or lymphoma cell lines of
varying phenotypes and differentiation stages. Interestingly,
the only exceptions were three multiple myeloma cell lines
whose FcRH4 mRNA and protein expression levels were
variable. In this regard, FcRH4 was originally identified as a
translocated gene in a myeloma cell line (16), although a role
for this gene in myeloma development has not been estab-
lished. This finding may also suggest that FcRH4 expression
persists during the earliest states of plasma cell differentiation
by FcRH4-bearing memory B cells.
Although CD27 is currently an accepted marker for
memory B cells in humans (6, 7), we found that most
FcRH4-bearing cells do not express this cell surface mole-
cule. This finding appears to differ from the conclusion
reached in two reports that describe coexpression of CD27
and FcRH4/IRTA1 (19, 31). Whereas the immunohis-
tochemical analysis of FcRH4  cells in tonsils with atypical
marginal zone hyperplasia indicated that these FcRH4 
cells do not express CD27, concomitant FcRH4 and CD27
expression was noted for B cells in normal tonsillar tissue
(32). However, the frequency of single versus dual FcRH4
and CD27 expression was not evaluated in this report. An
earlier study which reported CD27 and FcRH4 coexpres-
sion employed polyclonal rabbit antibodies directed against
a cytoplasmic FcRH4 epitope, therefore requiring fixation
and permeabilization for flow immunocytometric analysis of
the cells (19). The resultant low intensity staining for
FcRH4 expression prevented an unambiguous discrimina-
tion of FcRH4-positive cells, and this may account for the
discrepancy between results obtained with the polyclonal
and monoclonal antibodies.
Marafioti and colleagues have identified a subpopulation
of memory B cells in the interfollicular T cell rich areas of
tonsillar and lymph node tissue sections on the basis of their
stellate or dendritic morphology (31) that may or may not
belong to the tissue-based subpopulation of memory B cells
that we describe here. The interfollicular B lymphocytes that
they describe share certain characteristics with the FcRH4-
bearing memory B cells, including the absence of CD27, rel-
atively large cell size, and variable region somatic hypermu-
tation, albeit at higher levels. However, other characteristics
of the FcRH4-bearing cells, including the expression of
CD21, CD23, and the CD80 and CD86 activation markers,
are not shared. The large FcRH4  and interfollicular B lym-
phocytes therefore could represent different subsets of mem-
ory B cells, or their apparent phenotypic differences may re-
flect differences in cell marker discrimination via the flow
immunocytometric and immunohistochemical methods em-
ployed for their characterization.
Higher levels of CCR1 and CCR5 mRNA accompany
the expression of FcRH4 as another discriminating feature of
the FcRH4  and FcRH4  memory B cells. These chemo-
kine receptors recognize an overlapping set of ligands that
include Mip-1 , MIP-1 , and RANTES (for review see
reference 33). Although these chemokines are commonly
viewed as T cell targeting factors, CCR1 and CCR5 expres-
sion and chemotactic responses to their ligands have also
been reported for B cells (34, 35). This pattern of chemokine
receptor expression suggests that FcRH4  memory B cells
and T cells could be attracted by the same chemokine gradi-
ents, thereby facilitating T cell–dependent activation of the
FcRH4  cells. The preferential expression of these two
chemokine receptors could also contribute to the lymphoep-
ithelial tissue localization of FcRH4  cells, because epithelial
cells and their stromal cell neighbors release these chemo-
kines in inflammatory responses (36).
In addition to their different phenotypic features and tis-
sue distribution, the FcRH4  and FcRH4  memory B cells
have different functional characteristics. The FcRH4  mem-
ory cells produce much higher levels of secreted antibodies
than FcRH4  memory cells when stimulated in vitro with T
cell derived cytokines. Together with their increased cell
size and activated state, this finding indicates that the
FcRH4  memory B cells are primed to undergo terminal
plasma cell differentiation. Nevertheless, these cells do not
express increased levels of the transcription factors that pro-
mote plasma cell differentiation, including the spliced isoform
of XBP-1, BLIMP-1, and IRF4. The possibility that expres-
sion of FcRH4 marks a common intermediate step between
memory B cell and plasma cell differentiation is not sup-
ported by analysis of cell surface FcRH4 expression following
stimulation of FcRH4  cells with cytokine combinations that
induce plasma cell differentiation. Our findings are thus more
consistent with the idea that FcRH4  and FcRH4  memory
B cells represent different sublineages of memory B cells.
Notably, the FcRH4  memory B cells undergo prolifer-
ation both in response to cytokines that simulate T-depen-
dent stimulation and to direct BCR cross-linking. In
contrast, their FcRH4  counterparts are preferentiallyJEM VOL. 202, September 19, 2005 789
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responsive to T-dependent stimulation; their unresponsive-
ness to BCR ligation could be attributable to the relatively
low levels of CD21 expression, becuase engagement of this
complement receptor has been shown to lower the threshold
requirement for BCR-mediated activation (37). Another at-
tractive possibility is that FcRH4 inhibits the proliferative
response to BCR ligation. Irrespective of the mechanisms
involved, our data indicate that FcRH4  cells are poised to
undergo plasma cell differentiation in response to T-depen-
dent stimulation, whereas FcRH4  memory B cells can be
activated equally well by T-dependent and T-independent
stimulation to mount an immediate proliferative response.
FcRH4 is structurally and functionally related to Fc RIIB
(15, 18), the low affinity receptor for IgG antibodies that is ex-
pressed on memory B cells. Studies in animal models implicate
Fc RIIB dysfunction in a number of pathological situations,
including enhanced antibody responses (38), enhanced IgG-
and IgE-induced anaphylactic reactions (39), hypersensitivity
to collagen-induced arthritis (40, 41), and development of
spontaneous systemic lupus erythematosus (42). Although no
FcRH4 orthologue is found in mice (43), three lines of evi-
dence implicate FcRH4 as a potentially important regulator of
memory B cell activation and proliferation in humans: (1) bio-
chemical analysis has established the potent inhibitory poten-
tial of the intracellular domain of FcRH4 (18); (2) FcRH4-
bearing memory B cells fail to proliferate in response to BCR
ligation; and (3) IRTA1/FcRH4 was identified as a transloca-
tion-associated gene in a multiple myeloma cell line (16),
wherein the signal peptide coding region and the 5  end of
FcRH4 were juxtaposed next to the constant region of the im-
munoglobulin   heavy chain, thereby effectively creating a
knockout FcRH4 allele. Collectively, these observations raise
the intriguing possibility that function-loss FcRH4 mutations
or failures in mechanisms that control FcRH4 expression may
contribute to B cell–mediated immunopathology.
MATERIALS AND METHODS
Monoclonal and polyclonal antibodies. Monoclonal anti-FcRH4 an-
tibodies were generated by hyperimmunizing mice with baculo virus–
derived recombinant protein corresponding to the extracellular domain of
FcRH4 and fusion of lymph node cells with the non–immunoglobulin-
producing Ag8-653 myeloma variant. 34 out of 120 hybridoma clones pro-
duced ELISA-reactive antibodies against recombinant FcRH4 extracellular
domain. Three of these produced antibodies that reacted with a subpopula-
tion of tonsillar B cells. Clone 2A6 antibodies were tested for FcRH4 spec-
ificity via FACS, immunoprecipitation, and Western blotting analyses per-
formed as described previously (44). F(ab )2 fragments of the 2A6 antibodies
generated by pepsin digest according to the manufacturer’s instructions
(Pierce Biotechnology) were coupled to biotin (Pierce Biotechnology) or
directly labeled with Alexa647 (Invitrogen). Anti-GFP antibodies were pur-
chased from Santa Cruz Biotechnology, Inc., and anti-HA antibodies were
obtained from Covance. Biotinylated anti-IgD, streptavidin-APC, and
Streptavidin-PE were purchased from Southern Biotechnology Associates,
polyclonal mouse anti–human immunoglobulin and F(ab )2 fragments of
mouse anti–human immunoglobulin were purchased from Jackson Immu-
noResearch, and any other antibodies were obtained from BD Biosciences.
B cell isolation, analysis, and culture. Blood, tonsil, spleen, and bone
marrow tissue samples were obtained from the human tissue procurement
service of the University of Alabama at Birmingham with Institutional
Review Board approval and informed consent according to the declara-
tion of Helsinki. Single cell suspensions were generated by tissue mincing,
filtration through 70  m wire mesh, and cell centrifugation on a ficoll-
hypaque gradient. Tonsillar B cells of  99% purity were obtained by us-
ing anti-CD19 coupled to magnetic beads (Miltenyi Biotec) followed by
magnetic separation. After labeling with the indicated monoclonal anti-
body combinations, the cells were analyzed by using a FACSCalibur in-
strument (BD Biosciences). For microscopic analysis of the FcRH4  and
FcRH4  populations, the cells were stained with anti-IgD, anti-CD38,
and anti-FcRH4 antibodies before isolation of FcRH4  and FcRH4  cells
using a MoFlow FACS sorter (DAKO Cytomation). The cells were spun
onto glass slides, stained with Wright-GIEMSA stain (Sigma-Aldrich) and
examined by light microscopy (magnification, 400). For electron micros-
copy (magnification  10,000), the cells were fixed in 2% glutaraldehyde,
followed by incubation in 1% osmium and dehydration in a graded alco-
hol series before embedding in spur resin. After staining, the sections were
treated with 2% uranyl acetate and Reynold’s lead citrate. For prolifera-
tion and immunoglobulin secretion assays, tonsillar B cells were obtained
by depleting non–B cells using the B cell Isolation Kit II (Miltenyi Bio-
tec). The B cells ( 99% purity) were stained as described above before
isolation of FcRH4  and FcRH4  cells using a MoFlow FACS sorter.
Memory B cell cultures were maintained in RPMI 1640 supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin/strep-
tomycin, and 50  M  -mercaptoethanol.
Sequence analysis of VH genes. First-strand complementary DNA
(cDNA) was generated by performing random primed RT-PCR on CD19 
memory B cells after FACS-sorting into IgD /CD38 /FcRH4  and IgD /
CD38 /FcRH4  subpopulations. For the first round of PCR amplification with
a high fidelity PCR polymerase (Invitrogen), a primer mix was used that recog-
nizes all VH gene family members and JH gene family members (12). The second
round of PCR amplification employed VH3-gene specific primers in conjunc-
tion with primers recognizing all six JH genes. PCR products were cloned into
pBlueScript for sequence analysis of the 264 nucleotides encompassing the
framework 1, 2, and 3 regions as well as the CDR1 and CDR2 regions of the
VH3 genes. Sequence analysis was performed using the international ImMuno-
GeneTics information system (IMGT) (http://imgt.cines.fr) (45).
Quantitative RT-PCR analysis. To prevent contamination with non–B
cells, tonsillar B cells were stained with an anti-CD20 monoclonal antibody
before subpopulation sorting and mRNA harvesting by using the RNeasy
Kit (QIAGEN). Random primed cDNA corresponding to 5,000 cells/reac-
tion was used as a template. Whenever possible, oligonucleotides were de-
signed to overlap exon–intron borders to avoid amplification of genomic
DNA. Primer sequences are described in Fig. S2 (available at http://
www.jem.org/cgi/content/full/jem.20050879/DC1). To eliminate contam-
inating genomic DNA, RNA preparations were treated with RNase-free
DNase (QIAGEN). Quantitative RT-PCR was performed using SYBR-
Green PCR Master Mix (Applied Biosystems) on a 7900HT Sequence De-
tection System (Applied Biosystems). Because the widely used transcripts of
GAPDH and  -actin can be subject to regulation, thus making them less
suitable for normalization (46), we analyzed transcripts for the large subunit of
the RNase polymerase 2 (RP2), GAPDH, G6PDH, and HPRT transcripts
in the memory B cell subpopulations. Because RP2 transcripts were found to
be the most reliable transcripts for normalization based on cell numbers, all
quantitative PCR reactions were normalized to RP2 expression.
Cell proliferation and immunoglobulin secretion assays. Cells
plated in triplicate at a density of 15,000 per round-bottom well in 96-well
plates were cultured for 40 h with 2  g/mL intact anti-immunoglobulin,
1.33  g/mL F(ab )2 anti-immunoglobulin, 60 ng/mL IL-2, 200 ng/mL IL-
10, 2  g/mL CD40L (R&D Systems), and/or 0.001% SAC (Sigma-
Aldrich) before addition of 1  Ci 3H-thymidine for an additional 10 h. CellsMEMORY B CELL SUBSETS IN HUMANS | Ehrhardt et al. 790
were harvested with a Basic96 Harvester (Skatron Instruments) and thymi-
dine incorporation measured with a Wallac liquid scintillation counter.
For immunoglobulin secretion analysis, cells (15,000/well) were plated
in triplicate in a volume of 150  L and incubated with the different stimuli
for 4 d before supernatant collection and addition to ELISA plates coated
with a mixture of mouse anti–human IgA, IgM, and IgG (2  g/mL). After
overnight incubation at 4 C, plates were washed and a secondary horseradish
peroxidase (HRP)-labeled goat anti–human immunoglobulin (Jackson Im-
munoResearch) antibody was added for 1 h at room temperature. The plates
were washed again and HRP-substrate added for 30 min before microplate
reader analysis at 405 nm. For ELISPOT assays, FcRH4  and FcRH4  cells
were cultured as described above for 4 d. The cultured cells were then
washed in HANKS balanced salt solution, plated on MultiScreen filter plates
(Millipore) coated with monoclonal anti-IgG, anti-IgA, or anti-IgM antibod-
ies, and incubated at 37 C for an additional 6 h. After incubation, the plates
were washed three times, then incubated with goat anti–human immuno-
globulin HRP-labeled antibodies for 1 h, and the assay developed using AEC
(Moss, Inc.) as substrate. Immunoglobulin-producing cells were counted us-
ing an ImmunoSpot Analyses instrument (Cellular Technology LTD).
Online supplemental material. Fig. S1 shows the oligonucleotide se-
quences used as primers for quantitative PCR analysis of the transcription
factors and chemokine receptors of FcRH4-positive and FcRH4-negative
memory B cells. Fig. S2 depicts FcRH4 expression by several multiple my-
eloma cell lines. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050879/DC1.
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